Overview

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Status:
Active, not recruiting
Trial end date:
2023-05-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Antibodies
Antibodies, Blocking
Antibodies, Monoclonal
Immunoglobulins
Ipilimumab
Nivolumab